A minority of patients with primary central nervous system lymphoma (PCNSL) achieve a complete response to therapy and most patients have a poor prognosis. A recent randomized phase II trial demonstrated that the addition of high-dose cytarabine to high-dose methotrexate increases the complete response rate and improves patient outcome.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Olson, J. E. et al. The continuing increase in the incidence of primary central nervous system non-Hodgkin lymphoma: a surveillance, epidemiology, and end results analysis. Cancer 95, 1504–1510 (2002).
Mead, G. M. et al. A medical research council randomized trial in patients with primary cerebral non-Hodgkin lymphoma: cerebral radiotherapy with and without cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy. Cancer 89, 1359–1370 (2000).
Nelson, D. F. et al. Non-Hodgkin's lymphoma of the brain: can high dose, large volume radiation therapy improve survival? Report on a prospective trial by the Radiation Therapy Oncology Group (RTOG): RTOG 8315. Int. J. Radiat. Oncol. Biol. Phys. 23, 9–17 (1992).
Batchelor, T. et al. Treatment of primary CNS lymphoma with methotrexate and deferred radiotherapy: a report of NABTT 96–07. J. Clin. Oncol. 21, 1044–1049 (2003).
Shah, G. D. et al. Combined immunochemotherapy with reduced whole-brain radiotherapy for newly diagnosed primary CNS lymphoma. J. Clin. Oncol. 25, 4730–4735 (2007).
Abrey, L. E., DeAngelis, L. M. & Yahalom, J. Long-term survival in primary CNS lymphoma. J. Clin. Oncol. 16, 859–863 (1998).
Gavrilovic, I. T., Hormigo, A., Yahalom, J., DeAngelis, L. M. & Abrey, L. E. Long-term follow-up of high-dose methotrexate-based therapy with and without whole brain irradiation for newly diagnosed primary CNS lymphoma. J. Clin. Oncol. 24, 4570–4574 (2006).
Abrey, L. E. et al. Intensive methotrexate and cytarabine followed by high-dose chemotherapy with autologous stem-cell rescue in patients with newly diagnosed primary CNS lymphoma: an intent-to-treat analysis. J. Clin. Oncol. 21, 4151–4156 (2003).
Fisher, B. et al. Secondary analysis of Radiation Therapy Oncology Group study (RTOG) 9310: an intergroup phase II combined modality treatment of primary central nervous system lymphoma. J. Neurooncol. 74, 201–205 (2005).
Ferreri, A. J. et al. High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomised phase 2 trial. Lancet 374, 1512–1520 (2009).
Acknowledgements
The authors wish to thank P. B. Johnston and B. P. O'neill for their assistance with the manuscript.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Ansell, S., Rajkumar, S. Trials and tribulations in primary CNS lymphoma. Nat Rev Clin Oncol 7, 125–126 (2010). https://doi.org/10.1038/nrclinonc.2010.9
Issue Date:
DOI: https://doi.org/10.1038/nrclinonc.2010.9
This article is cited by
-
Flows and flaws in primary central nervous system lymphoma
Nature Reviews Clinical Oncology (2010)
-
Author reply: Flows and flaws in primary CNS lymphoma
Nature Reviews Clinical Oncology (2010)
